How it works
How Much Does Chemotherapy for pancreatic cancer Cost in China?
Chemotherapy for pancreatic cancer in China typically costs from $4,500 to $10,500. Total expenses depend on the drug regimen, hospital tier, and whether medications are domestic or imported. Patients save approximately 73% compared to the United States, where the average cost is $28,000. These prices often include drug administration and clinical oversight.
- Regimen type: Advanced combination therapies like FOLFIRINOX generally increase costs by 30-50%.
- Medication source: Branded imported targeted therapies cost significantly more than domestic generic options.
- Hospital tier: Treatment at elite Grade III, Class A hospitals trends toward higher pricing.
- Diagnostic phase: Pre-treatment biopsies and imaging typically add between $2,000 and $5,000.
Bookimed Expert Insight: Choosing a JCI-accredited center like Fuda Cancer Hospital offers Western-standard care at significantly lower costs. Specialized clinics in Guangzhou often provide integrated technologies like NanoKnife and cryosurgery. These advanced options are frequently used alongside chemotherapy to manage late-stage pancreatic cases. Many top Chinese centers now include free airport transfers and interpreters for international patients.
| China | Turkey | Austria | |
|---|---|---|---|
| Chemotherapy for pancreatic cancer | ≈ $4,500 | from $1,500 | ≈ $9,000 |
Discover the Best Chemotherapy for pancreatic cancer Clinics in China: 3 Verified Options and Prices
Chemotherapy for pancreatic cancer Overview in China
- Chemotherapy - from $5,000This therapy treats cancer by using drugs to destroy cancer cells and prevent their growth.
- Chemoembolization of the liver - from $7,500This therapy combines cancer-killing drugs and blockage of blood supply to shrink liver tumors rapidly and effectively.
- Chemotherapy for lung cancer - from $5,000This therapy utilizes drugs to kill lung cancer cells, often given via injection or oral tablet, enhancing survival rates.
Day 1
- Arrive at the clinic.
- Meet with the oncologist for consultation.
- Complete blood tests and scans.
- Discuss chemotherapy plan with oncologist.
Day 2
- Begin first chemotherapy session.
- Chemotherapy is administered intravenously.
- Each session lasts for about 2-3 hours.
- No anesthesia is required for chemotherapy.
Day 3-5
- Rest and recuperate at home.
- Manage symptoms and side effects of chemotherapy.
Week 2
- Return to clinic for second chemotherapy session.
- Monitor progress and adjust treatment plan if necessary.
Weeks 3-6
- Continue chemotherapy sessions on a weekly basis.
- Manage side effects and maintain a healthy diet.
Week 7
- Evaluate treatment progress with oncologist.
- Additional scans and tests may be required.
Week 8-12
- Continue weekly chemotherapy sessions.
- Manage side effects and maintain physical health.
Weeks 12-16
- Gradual return to normal activities is possible.
- Continue to manage side effects and diet.
Week 17 onwards
- End of chemotherapy sessions.
- Follow-up with oncologist for regular check-ups.
- Gradually return to work and other activities.
Please note that each patient"s journey is unique and the timeline may vary based on the patient"s response to treatment.
- Bookimed deposit: $200 or €200.
- Clinic deposit: Pay a set percentage in advance.
Our Doctors
View all Doctors
Liao Zhengyin
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.

Luo Xiaoping
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).

He Weibing
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.

Xiao Yueyong
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
Video Stories from Bookimed Patients
Reviews about Bookimed: Discover Patients' Insights
All reviews


Share this content
Anna Leonova








